Table 1– Baseline demographic and clinical characteristics of patients completing 12 weeks of riociguat treatment
CTEPHPAHTotal
Subjects413172
Demographic data
 Age yrs63.0 (56.0–70.0)62.0 (49.0–69.0)63.0 (50.0–70.0)
 Ethnic origin white %41 (100)31 (100)72 (100)
 Females %18 (44)21 (68)39 (54)
 Weight kg75.0 (66.0–85.0)72.0 (63.0–86.0)74.0 (63.5–85.0)
 Height cm170.0 (165.0–174.0)166.0 (160.0–172.0)169.5 (163.5–174.0)
 Body mass index kg·m−224.7 (23.3–28.1)25.8 (23.4–30.5)24.8 (23.4–29.3)
Functional status
 WHO functional class
  I0 (0)0 (0)0 (0)
  II10 (24)5 (16)15 (21)
  III31 (76)25 (81)56 (78)
  IV0 (0)1 (3)1 (1)
 6-min walk distance m390.0 (330.0–441.0)337.0 (215.0–406.0)359.0 (300.0–420.0)
Right heart catheterisation
 Mean pulmonary arterial pressure mmHg44.0 (38.0–51.0)48.0 (36.0–55.0)45.5 (38.0–53.0)
 Pulmonary vascular resistance dyn·s·cm−5686 (516–859)836 (511–1173)727 (513–996)
 Pulmonary capillary wedge pressure mmHg8.0 (5.0–12.0)8.0 (5.0–10.0)8.0 (5.0–11.0)
 Systemic vascular resistance# dyn·s·cm−51721 (1346–2067)1744 (1456–2275)1730 (1368–2143)
 Cardiac index L·min−1·m−22.31 (1.94–2.68)2.13 (1.84–2.50)2.19 (1.92–2.54)
 Pulmonary/systemic vascular resistance# %44.1 (34.3–50.2)48.0 (32.2–58.7)45.7 (33.3–52.4)
  • Data are presented as n, n (%) or median (interquartile range). CTEPH: chronic thromboembolic pulmonary hypertension; PAH: pulmonary arterial hypertension; WHO: World Health Organization. #: measurements required to calculate baseline systemic vascular resistance were available for 66 patients (CTEPH n = 40; PAH n = 26).